Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris

This study has been completed.
Information provided by (Responsible Party):
Intrepid Therapeutics, Inc. Identifier:
First received: April 11, 2013
Last updated: May 29, 2014
Last verified: May 2014

This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in subjects with acne vulgaris ages 12 years or older.

Condition Intervention Phase
Acne Vulgaris
Drug: cortexolone 17α-propionate
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris

Resource links provided by NLM:

Further study details as provided by Intrepid Therapeutics, Inc.:

Primary Outcome Measures:
  • Change in HPA Axis Response to Cosyntropin [ Time Frame: Baseline and Day 14 ] [ Designated as safety issue: No ]
    Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin (Cosyntropin Stimulation Test - CST). HPA axis suppression is defined as a post-stimulation serum cortisol level ≤ 18 μg/dL at Day 14.

  • Change in PK profiles of cortexolone 17α-propionate and cortexolone [ Time Frame: Baseline and Day 14 ] [ Designated as safety issue: No ]
    Concentration-time profiles of cortexolone 17α-propionate and its metabolite, cortexolone, in plasma.

Enrollment: 42
Study Start Date: April 2013
Study Completion Date: November 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cortexolone 17α-Propionate
Topical cream, 1.0% concentration, applied every twelve hours
Drug: cortexolone 17α-propionate
Other Name: CB-03-01


Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has moderate to severe facial acne vulgaris as determined by the Investigator's Global Assessment (IGA) and obvious acne on the chest and/or back at study start.
  • Subject has facial acne vulgaris (including the nose) with a minimum number of inflammatory lesions (papules, pustules, and nodules/cysts) and a minimum number of non-inflammatory lesions (open and closed comedones) at study start.
  • Females must be post-menopausal, surgically sterile or using highly effective birth control methods with a negative urine pregnancy test (UPT) at study start.
  • Subject must be in general good health in the opinion of the investigator, with normal renal function, based on screening physical examination, medical history, and clinical laboratory values.

Exclusion Criteria:

  • Subject is pregnant, lactating, or is planning to become pregnant during the study.
  • Subject is 12-20 years of age and has a Body Mass Index (BMI) for age percentile > 85%.
  • Subject is > 20 years of age and has a BMI > 32.0 kg/m2.
  • Subject has used tobacco, smoking cessation products, or products containing nicotine within three months prior to study start.
  • Except for the use of contraceptives, subject has used any prescription drug or herbal product within 14 days prior to dosing, any non-prescription drug or vitamin or mineral supplements within 7 days prior to study start; any known enzyme-inducer, enzyme-inhibitor, or reported chronic exposure to enzyme-inducers such as paint solvents or pesticides within 30 days of study start.
  • Subject has used topical anti-acne medications containing retinoids such as tazarotene, adapalene or tretinoin, within four weeks of study start.
  • Subject has used the following systemic anti-acne medications: antibiotics within two weeks of study start, spironolactone within four weeks of study start, or retinoid therapy within three months of study start.
  • Subject has any skin or medical condition, including facial hair that could interfere with the evaluation of the test article or requires the use of interfering topical or systemic therapy.
  • Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the study.
  • Subject has used light treatments, microdermabrasion or chemical peels to the face, chest and back within eight weeks of study start.
  • Subject cannot avoid any type of strenuous exercise (swimming, running, team sports, etc.,) or the use of hot tubs/saunas from study start to the end of the study.
  • Subject has received an investigational drug or been treated with an investigational device within 30 days prior to study start.
  • Subject is currently enrolled in an investigational drug or device study.
  • Subject has used topical corticosteroids (including inhaled and intranasal corticosteroids) within two weeks of study start.
  • Subject has used systemic corticosteroids (including intramuscular and intralesional injections) within four weeks of study start.
  • Subject has an irregular sleep schedule or works night shifts.
  • Subject has experienced significant blood loss within 60 days or has donated plasma within 72 hours prior to study start.
  • Subject tests positive at Screening for human immunodeficiency virus (HIV) or is known to be seropositive for HIV.
  • Subject tests positive at Screening for hepatitis B surface antigen, hepatitis C antibody or has a history of a positive result.
  • Subject had major surgery within 30 days prior to study start or plans to have surgery during the study.
  • Subject has participated in a previous CB-03-01 study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01831960

United States, Idaho
Northwest Clinical Trials, Inc.
Boise, Idaho, United States
United States, Indiana
Shideler Clinical Research Center
Carmel, Indiana, United States
United States, Michigan
Michigan Center for Research Corp.
Clinton Township, Michigan, United States
Sponsors and Collaborators
Intrepid Therapeutics, Inc.
Study Director: Syd Dromgoole, Ph.D. Therapeutics, Inc.
  More Information

No publications provided

Responsible Party: Intrepid Therapeutics, Inc. Identifier: NCT01831960     History of Changes
Other Study ID Numbers: 171-7151-202
Study First Received: April 11, 2013
Last Updated: May 29, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Intrepid Therapeutics, Inc.:
cortexolone 17α-propionate

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Facial Dermatoses
Sebaceous Gland Diseases
Skin Diseases processed this record on March 02, 2015